Amendments to the Specification

Please amend page 1, line 1 as follows:

This application is a divisional application of U.S. Patent <u>6,919,083</u> Application <u>10/049,086</u> filed on February 6, 2002, which is the National Stage of International Patent Application PCT/GB00/02976 filed on August 7, 2000.

Fifth paragraph of page and the Please amend the first, second, third, and fourth paragraphs of Page 2 (lines 6-25) as follows:

Allogoz/ob

A substantially homologous nucleic acid sequence is a sequence which can be transcribed and/or translated to provide an amino acid sequence which is substantially homologous to at least a part of a-surface an antigen present on of ISAV.

Preferably the substantially homologous amino acid is at least 70% homologous with a part of a-surface an antigen of ISAV which is capable of inducing an immune response.

More preferably the substantially homologous amino acid sequence is at least 80% homologous with a part of a surface an antigen of ISAV and can induce an immune response.

Most preferably the substantially homologous amino acid sequence is at least 90% homologous with a part of a surface an antigen of ISAV and can induce an immune response.

On page 3, please amend paragraphs 2, 3, 4, 6 (lines 6-28) as follows:

BH8/02/06

Preferably the substantially homologous nucleotide sequence is at least 60 % homologous with a part of a nucleic acid sequence of a-surface an antigen of ISAV and the translation product thereof is capable of inducing an immune response.

Preferably the substantially homologous nucleotide sequence encodes <u>is</u> at least 70 % homologous with a part of a nucleic acid sequence of <u>a surface an</u> antigen of ISAV, and the translation product of which is capable of inducing an immune response.

More preferably the substantially homologous nucleotide sequence encodes <u>is</u> at least 80 % homologous with a part of a nucleic acid sequence of <u>a surface an</u> antigen of ISAV and the translation product of which is capable of inducing an immune response.

Most preferably the substantially homologous nucleotide sequence is at least 90 % homologous to a part of a nucleic acid sequence of a surface an antigen of ISAV, the translation product of which is capable of inducing an immune response.

Please amend page 6, lines 13-20 as follows:

Figure 6c is the amino acid sequence (M3) which is translated from the unspliced nucleic acid sequence of ISA3mx as shown in Figure 5.

Figure 7 is the nucleotide sequence of ISA4ha (SEQ ID NO:9).

Figure 8 is the amino acid sequence of ISA4ha (SEQ ID NO: 10).

In addition, information detailing the specific molecular weight (MW) and theoretical isoelectric focusing points (pl) is given at the foot of the respective amino acid sequence listings.